S100A9 and atopic eczema: Both SERPINB3 and S100A9 are modulators of inflammatory response [39–41], highly inducible in keratinocytes, and have been found to be de-regulated in inflammatory skin diseases such as venous ulcers [42], psoriasis [41, 43], atopic dermatitis [39, 41], and skin cancer [40].